NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.

106Background: CUP has a poor prognosis with a median survival of less than 12 months. Given the recent approval of immune checkpoint inhibitors in several cancer types, we performed a multicenter ...